

Dr. Olga Pol is the Leader of the Molecular Neuropharmacology Group at the **Sant Pau Research Institute (IR SANT PAU)** and affiliated research professor at the **Institute of Neurosciences of the Autonomous University of Barcelona (UAB)**. She leads a research group dedicated to the study of pain and to developing new pharmacological strategies to inhibit chronic pain and the emotional and mental disorders that accompany it, such as anxiety, depression, or even memory loss. After earning her PhD in Neurosciences at the UAB, she worked for more than a decade as a researcher at the **Municipal Institute of Medical Research–Biomedical Research Park of Barcelona (IMIM-PRBB)**. In 2005, she founded the Molecular Neuropharmacology Group at IR SANT PAU and the UAB, which she has led ever since and where she carries out her scientific activity. She has done international research stays at leading neuroscience centers such as the **University of Washington** (Seattle, USA), **Johns Hopkins Hospital** (Baltimore, USA), and the **University of São Paulo** (Ribeirão Preto, Brazil).

Throughout her career, Dr. Pol has published more than **104 scientific articles** and is an **editor** of the journals *Frontiers in Pharmacology* and *Antioxidants*. She is also a member of the board of the *European Academy for Molecular Hydrogen Research in Biomedicine* and belongs to various scientific societies (IASP, SFN, SED, SEF). She has led numerous research projects funded through competitive national and international calls, supervised **38 doctoral and master's theses**, and given presentations at international conferences. H-index = 30.

Her main research lines include the study of molecules and cellular pathways that can relieve pain more effectively and safely, as well as new therapeutic possibilities based on the action of **medicinal gases**—such as molecular hydrogen, endogenous carbon monoxide, and hydrogen sulfide—in which Dr. Pol is a **pioneer**. She also investigates how to enhance the analgesic effects of conventional drugs such as **opioids and cannabinoids**, with the goal of alleviating pain and improving the quality of life of people living with chronic pain.